论文部分内容阅读
凯美纳(埃克替尼),一个由一群怀揣着“做中国人自己的抗癌药”梦想的海归博士所研发的创新抗癌药,历经十年成功上市,在收获荣誉的同时,也创造了可观的业绩。让我们来看这样一份新药研发历程表:2002年8月,丁列明放弃美国的高薪工作回国创业。2003年1月,贝达药业股份有限公司在杭州正式成立,开始凯美纳的研发。2006年6月,凯美纳获得国家药品食品监督管理局批准进入临床试验。2009年2月,三期临床试验正式启动和进口同类药——易瑞沙的头对头双盲比试。2011年6月,凯美纳获得国家食品药品
Kaimei Na (Icnomycin), an innovative anti-cancer drug developed by a group of Dr. Gui Gui, who carries his dream of “doing Chinese anti-cancer medicine”, has been successfully listed for over 10 years. , Also created a considerable performance. Let us look at such a new drug R & D history table: In August 2002, Ding Liuming give up the United States high-paying job to start a business. January 2003, Beida Pharmaceutical Co., Ltd. was formally established in Hangzhou, Kai-na began R & D. June 2006, Kaimei Na access to the State Drug Administration approved clinical trials. February 2009, Phase III clinical trials officially launched and imported similar drugs - Iressa’s head-to-head double-blind trial. June 2011, Kemei Na access to national food and drug